Farnesyl Transferase Inhibitors: From Targeted Cancer Therapeutic to a Potential Treatment for Progeria

Enzymes

Volumn 29, Issue , 2011, Pages 275-303

  Bishop, W Robert ^a   Doll, Ronald ^b   Kirschmeier, Paul ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DREW UNIVERSITY   (United States)

Author keywords

Farnesyl transferase inhibitors; Farnesylated proteins; Hutchinson Gilford Progeria Syndrome; Lamin A; Lonafarnib; Ras mutations in cancer; Tipifarnib

Indexed keywords

EID: 79960219823     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381339-8.00015-9     Document Type: Chapter

References (129)

1. Casey P.J., Solski P.A., Der C.J., Buss J.E. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989, 86:8323-8327.
2. Gibbs J.B. Ras C-terminal processing enzymes-new drug targets. Cell 1991, 65:1-4.
3. Barbacid M. Ras genes. Annu Rev Biochem 1987, 56:779-827.
4. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
5. Bos J.L. Detection of ras oncogenes using PCR. PCR Technology 1989, 228. Stockton Press, New York, NY. H.A. Erlich (Ed.).
6. Rivera M., Ricarte-Filho J., Knauf J., Shaha A., Tuttle M., Fagin J.A., Ghossein R.A. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs. infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010, 23:1191-1200.
7. Willumsen B., Norris K., Papageorge A., Hubbert N.L., Lowy D.R. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J 1984, 3:2581-2585.
8. Willumsen B.M., Christensen A., Hubbert N.L., Papageorge A.G., Lowy D.R. The p21 ras C-terminus is required for transformation and membrane association. Nature 1984, 310:583-586.
9. Hancock J., Magee A., Childs J., Marshall C. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57:1167-1177.
10. Casey P.J., Solski P.A., Der C.J., Buss J.E. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989, 86:8323-8327.
11. Zhang F.L., Kirschmeier P., Carr D., James L., Bond R.W., Wang L., Patton R., Windsor W.T., Syto R., Zhang R., Bishop W.R. Characterization of H, K and N-ras as in vitro substrates for isoprenyl protein transferases. J Biol Chem 1997, 272:10232-10239.
12. Lowe P.N., Sydenham M., Page M.J. The Ha-ras protein, p21, is modified by a derivative of mevalonate and methyl-esterified when expressed in the insect/baculovirus system. Oncogene 1990, 5:1045-1048.
13. Otto J.C., Kim E., Young S.G., Casey P.J. Cloning and characterization of a mammalian prenyl protein-specific protease. J Biol Chem 1999, 274:8379-8382.
14. Dai Q., Choy E., Chiu V., Romano J., Slivka S.R., Steitz S.A., Michaelis S., Philips M.R. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J Biol Chem 1998, 273:15030-15034.
15. Reiss Y., Goldstein J.L., Serabra M.C., Casey P.J., Brown M.S. Inhibition of purified p21ras farnesyl: proteintransferase by Cys-AAX tetrapeptides. Cell 1990, 62:81-88.
16. Schaber M.D., O'Hara M.B., Garsky V.M., Mosser S.C., Bergstorm D.J., Moores S.L., Marshall M.S., Friedman P.A., Dixon R.A., Gibbs J.B. Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. J Biol Chem 1990, 265:14701-14704.
17. Moores S.L., Schaber M.D., Mosser S.D., Rands E., O'Hara M.B., Garsky V.M., Mardhall M.S., Pompliano D.L., Gibbs J.B. Sequence dependence of protein isoprenylation. J Biol Chem 1991, 266:14603-14610.
18. Goldstein J.L., Brown M.S., Stradley S.J., Reiss Y., Gierasch L.M. Nonfarnesylated tetrapeptide inhibition of protein farnesyltransferase. J Biol Chem 1991, 266:15575-15578.
19. Brown M.S., Goldstein J.L., Paris K.J., Burnier J.P., Masters J.C. Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation. Proc Natl Acad Sci USA 1992, 89:8313-8316.
20. Kohl N.E., Mosser S.D., deSolms J., Giuliani D.L., Pompliano D.L., Grahm S.L., Smith R.L., Scolnick E.M., Oliff A. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260:1934-1937.
21. Graham S. Inhibitors of protein farnesylation: a new approach to cancer chemotherapy. Expert Opin Ther Pat 1995, 5:1269-1285.
22. Ayral-Kaloustain S., Skotnicki J.S. Ras farnesyltransferase inhibitors. Annual Reports in Medicinal Chemistry 1996, Vol. 31:171-180. Academic Press, San Diego. J. Bristol (Ed.).
23. Leonard D.M. Ras farnesyltransferase: a new therapeutic target. J Med Chem 1997, 40:2971-2990.
24. Williams T.M., Dinsmore C.J. Farnesyl transferase inhibitors: design of a new class of cancer chemotherapeutic agents. Adv Med Chem 1999, 4:273-314.
25. Liao H., Winkfein R.J., Mack G., Rattner J.B., Yen T.J. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol 1995, 130:507-518.
26. Doll R.J. Inhibition of farnesyl protein transferase-a review of the recent patent literature. IDrugs 2001, 4:1382-1388.
27. Strickland C.L., Weber P.C. Farnesyl protein transferase: a review of structural studies. Curr Opin Drug Discov Devel 1999, 2:475-483.
28. Reid T.S., Beese L.S. Crystal structures of the anticancer clinical candidates R11577 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry 2004, 43:6877-6884.
29. Strickland C.L., Weber P.C., Windsor W.T., Wu Z., Le H.V., Albanese M.M., Alvarez C.S., Cesarz D., del Rosario J., Deskus J., Mallams A.K., Njoroge F.G., Piwinski J.J., Remiszewski S., Rossman R.R., Taveras A.G., Vibulbhan B., Doll R.J., Girijavallabhan V.M., Ganguly A.K. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J Med Chem 1999, 42:2125-2135.
30. Zhu H.Y., Cooper A.B., Desai J., Njoroge G., Kirschmeier P., Bishop W.R., Strickland C., Hruza A., Doll R.J., Girijavallabhan V.M. Discovery of C-imidazole azaheptapyridine FPT inhibitors. Bioorg Med Chem Lett 2010, 20:1134-1136.
31. Fletcher S., Keaney E.P., Cummings C.G., Blaskovich M.A., Hast M.A., Glenn M.P., Chang S.-Y., Bucher C.J., Floyd R.J., Katt W.P., Gelb M.H., Van Voorhis W.C., Beese L.S., Sebti S.M., Hamilton A.D. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. J Med Chem 2010, 53:6867-6888.
32. Bendale P., Olepu S., Suryadevara P.K., Bulbule V., Rivas K., Nallan L., Smart B., Yokoyama K., Ankala S., Pendyala R.P., Floyd D., Lombardo L.J., Williams D.K., Buckner F.S., Chakrabarti D., Verlinde C.L.M.J., Van Voorhis W.C., Gelb M.H. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem 2007, 50:4585-4605.
33. Bulbule V.J., Rivas K., Verlinde C.L.M.J., Van Voorhis W.C., Gelb M.H. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem 2008, 51:384-387.
34. Manne V., Lee F.Y., Bol D.K., Gullo-Brown J., Fairchild C.R., Lombardo L.J., Smykla R.A., Vite G.D., Wen M.L., Yu C., Wong T.W., Hunt J.T. Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models. Cancer Res 2004, 64:3974-3980.
35. Lackner M.R., Kindt R.M., Carroll P.M., Brown K., Cancilla M.R., Chen C., de Silva H., Franke Y., Guan B., Heuer T., Hung T., Keegan K., Lee J.M., Manne V., O'Brien C., Parry D., Perez-Villar J.J., Reddy R.K., Xiao H., Zhan H., Cockett M., Plowman G., Fitzgerald K., Costa M., Ross-Macdonald P. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 2005, 7:325-336.
36. Bishop W.R., Bond R., Petrin J., Wang L., Patton R., Doll R., Njoroge G., Catino J., Schwartz J., Windsor W., Syto R., Schwartz J., Carr D., James L., Kirschmeier P. Novel tricyclic inhibitors of farnesyl protein transferase: biochemical characterization and inhibition of ras modification in transfected Cos cells. J Biol Chem 1995, 270:30611-30618.
37. Sepp-Lorenzino L., Ma Z., Rands E., Kohl N.E., Gibbs J.B., Oliff A., Rosen N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995, 55:5302-5309.
38. Ashar H.R., James L., Gray K., Carr D., McGuirk M., Maxwell E., Black S., Armstrong L., Doll R.J., Taveras A.G., Bishop W.R., Kirschmeier P. The farnesyl transferase inhibitor SCH 66336 induces a G2/M or G1 phase pause in sensitive human tumor cell lines. Exp Cell Res 2000, 262:17-27.
39. Moasser M.M., Sepp-Lorenzino L., Kohl N.E., Oliff A., Balog A., Su D.S., Danishefsky S.J., Rosen N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998, 95:1369-1374.
40. Shi B., Yaremko B., Hajian G., Terracina G., Bishop W.R., Liu M., Nielsen L.L. The farnesyl protein transferase inhibitor lonafarnib synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000, 46:387-393.
41. Nakamura K., Yamaguchi A., Namiki M., Ishihara H., Nagasu T., Kowalczyk J.J., Garcia A.M., Lewis M.D., Yoshimatsu K. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel. Oncol Res 2001, 12:477-484.
42. Peters D.G., Hoover R.R., Gerlach M.J., Koh E.Y., Zhang H., Choe K., Kirschmeier P., Bishop W.R., Daley G.Q. Activity of the farnesyl protein transferase inhibitor SCH 66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001, 97:1404-1412.
43. Nakajima A., Tauchi T., Sumi M., Shimamoto T., Bishop W.R., Ohyashiki K. Efficacy of SCH 66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL positive cells. Mol Cancer Ther 2003, 2:219-224.
44. Hoover R.R., Mahon F.X., Melo J.V., Daley G.Q. Overcoming STI571-resistance with the farnesyl transferase inhibitor SCH 66336. Blood 2002, 100:1068-1071.
45. Martin L.A., Head J.E., Pancholi S., Salter J., Quinn E., Detre S., Kaye S., Howes A., Dowsett M., Johnston S.R. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther 2007, 6:2458-2467.
46. James G.L., Goldstein J.L., Brown M.S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995, 270:6221-6226.
47. Whyte D.B., Kirschmeier P., Hockenberry T.N., Nunez-Oliva I., James L., Catino J.J., Bishop W.R., Pai J.K. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997, 272:14459-14464.
48. Rowell C.A., Kowalczyk J.J., Lewis M.D., Garcia A.M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997, 272:14093-14097.
49. Corrigan D.P., Kuszczak D., Rusinol A.E., Thewke D.P., Hrycyna C.A., Michaelis S., Sinensky M.S. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem J 2005, 387:129-138.
50. Hancock J.F., Cadwallader K., Paterson H., Marshall C.J. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J 1991, 10:4033-4039.
51. Lebowitz P.F., Sakamuro D., Prendergast G.C. Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied substratum attachment. Cancer Res 1997, 57:708-713.
52. Liu M., Bishop W.R., Nielsen L.L., Bryant M.S., Kirschmeier P. Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models. Methods Enzymol 2001, 333:306-318.
53. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P., Malkowski M., Ferrari E., Nielsen L., Prioli N., Dell J., Sinha D., Syed J., Korfmacher W.A., Nomeir A.A., Lin C.C., Taveras A.G., Doll R.J., Njoroge F.G., Mallams A.K., Remiszewski S., Catino J.J., Girijavallabhan V.M., Kirschmeier P., Bishop W.R. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998, 58:4947-4956.
54. Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., deSolms S.J., Giuliani E.A., Gomez R.P., Graham S.L., Hamilton K. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995, 1:792-797.
55. Mangues R., Corral T., Kohl N.E., Symmans W.F., Lu S., Malumbres M., Gibbs J.B., Oliff A., Pellicer A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 1998, 58:1253-1259.
56. Omer C.A., Chen Z., Diehl R.E., Conner M.W., Chen H.Y., Trumbauer M.E., Gopal-Truter S., Seeburger G., Bhimnathwala H., Abrams M.T., Davide J.P., Ellis M.S., Gibbs J.B., Greenberg I., Koblan K.S., Kral A.M., Liu D., Lobell R.B., Miller P.J., Mosser S.D., O'Neill T.J., Rands E., Schaber M.D., Senderak E.T., Oliff A., Kohl N.E. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res 2000, 60:2680-2688.
57. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., Venet M., Sanz G., Poignet H., Skrzat S., Devine A., Wouters W., Bowden C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001, 61:131-137.
58. Reichert A., Heisterkamp N., Daley G.Q., Groffen J. Treatment of BCR/ABLpositive ALL in P190 transgenic mice with the farnesyl transferase inhibitor SCH 66336. Blood 2001, 97:1399-1403.
59. Taylor S.A., Marrinan C.H., Liu G., Nale L., Bishop W.R., Kirschmeier P., Liu M., Long B.J. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo. Gynecol Oncol 2008, 109:97-106.
60. Liu G., Taylor S.A., Marrinan C.H., Hsieh Y., Bishop W.R., Kirschmeier P., Long B.J. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. Int J Cancer 2009, 125:2711-2720.
61. Liu G., Marrinan C.H., Taylor S.A., Black S., Basso A.D., Kirschmeier P., Bishop W.R., Liu M., Long B.J. Enhancement of the anti-tumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH 66336). Anticancer Drugs 2007, 18:923-931.
62. Huber H.E., Robinson R.G., Watkins A., Nahas D.D., Abrams M.T., Buser C.A., Lobell R.B., Patrick D., Anthony N.J., Dinsmore C.J., Graham S.L., Hartman G.D., Lumma W.C., Williams T.M., Heimbrook D.C. Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors. J Biol Chem 2001, 276:24457-24465.
63. Ashar H.R., James L., Gray K., Carr D., Black S., Armstrong L., Bishop W.R., Kirschmeier P. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with microtubules. J Biol Chem 2000, 275:30451-30457.
64. Basso A.D., Mirza A., Liu G., Long B.J., Bishop W.R., Kirschmeier P. The farnesyl transferase inhibitor (FTI) SCH 66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 2005, 280:31101-31108.
65. Roberts P.J., Mitin N., Keller P.J., Chenette E.J., Madigan J.P., Currin R.O., Cox A.D., Wilson O., Kirschmeier P., Der C.J. Rho family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J Biol Chem 2008, 283:25150-25163.
66. Lebowitz P.F., Casey P.J., Prendergast G.C., Thissen J.A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 1997, 272:15591-15594.
67. Lebowitz P.F., Davide J.P., Prendergast G.C. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 1995, 15:6613-6622.
68. Du W., Prendergast G.C. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 1999, 59:5492-5496.
69. Chen Z., Sun J., Pradines A., Favre G., Adnane J., Sebti S.M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 2000, 275:17974-17978.
70. Liu A., Du W., Liu J.P., Jessell T.M., Prendergast G.C. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 2000, 20:6105-6113.
71. Gromov P.S., Madsen P., Tomerup N., Celis J.E. A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog of rheb. FEBS Lett 1995, 377:221-226.
72. Basso A.D., Mirza A., Liu G., Long B.J., Bishop W.R., Kirschmeier P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 2005, 280:31101-31108.
73. Clark G.J., Kinch M.S., Rogers-Graham K., Sebti S.M., Hamilton A.D., Der C.J. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 1997, 272:10608-10615.
74. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003, 5:578-581.
75. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
76. Long X., Lin Y., Ortiz-Vega S., Yonezawa K., Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 2005, 15:702-713.
77. Castro A.F., Rebhun J.F., Clark G.J., Quilliam L.A. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003, 278:32493-32496.
78. Mavrakis K.J., Zhu H., Silva R.L., Mills J.R., Teruya-Feldstein J., Lowe S.W., Tam W., Pelletier J., Wendel H.G. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 2008, 22:2178-2188.
79. Bessette D.C., Qiu D., Pallen C.J. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 2008, 27:231-252.
80. Cates C.A., Michael R.L., Stayrook K.R., Harvey K.A., Burke Y.D., Randall S.K., Crowell P.L., Crowell D.N. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett 1996, 110:49-55.
81. Zeng Q., Si X., Horstmann H., Xu Y., Hong W., Pallen C.J. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem 2000, 275:21444-21452.
82. Wang J., Kirby C.E., Herbst R. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem 2002, 277:46659-46668.
83. Liang F., Liang J., Wang W.Q., Sun J.P., Udho E., Zhang Z.Y. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 2007, 282:5413-5419.
84. Yao X., Anderson K.L., Cleveland D.W. The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules. J Cell Biol 1997, 139:435-447.
85. Wood K.W., Sakowicz R., Goldstein L.S., Cleveland D.W. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell 1997, 91:357-366.
86. Hussein D., Taylor S.S. Farnesylation of CENP-F is required for G2/M progression and degradation after mitosis. J Cell Sci 2002, 115:3403-3414.
87. Crespo N.C., Ohkanda J., Yen T.J., Hamilton A.D., Sebti S.M. The farnesyltransferase inhibitor FTI02153 blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 2001, 276:16161-16167.
88. Schafer-Hales K., Iaconelli J., Snyder J.P., Prussia A., Nettles J.H., El-Naggar A., Khuri F.R., Giannakakou P., Marcus A.I. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 2007, 6:1317-1328.
89. Aebi U., Cohn J., Buhle L., Gerace L. The nuclear lamina is a meshwork of intermediate-type filaments. Nature 1986, 323:560-564.
90. Ulitzur N., Harel A., Feinstein N., Gruenbaum Y. Lamin activity is essential for nuclear envelope assembly in a Drosophila embryo cell-free extract. J Cell Biol 1992, 119:17-25.
91. Wolda S.L., Glomset J.A. Evidence for modification of lamin B by a product of mevalonic acid. J Biol Chem 1998, 263:5997-6000.
92. Beck L.A., Hosick T.J., Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 1990, 110:1489-1499.
93. Weber K., Plessmann U., Traub P. Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. FEBS Lett 1989, 257:411-414.
94. Basso A., Kirschmeier P., Bishop W.R. Farnesyl transferase inhibitors. J Lipid Res 2006, 47:15-31.
95. Eskens F.A., Awada A., Cutler D.L., de Jonge M.J., Luyten G.P., Faber M.N., Statkevich P., Sparreboom A., Vewweij J., Hanauske A.R., Piccart M. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001, 19:1167-1175.
96. Punt C.J., van Maanen L., Bol C.J., Seifert W.F., Wagener D.J. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 2001, 12:193-197.
97. Adjei A.A., Erlichman C., Davis J.N., Cutler D.L., Sloan J.A., Marks R.S., Hanson L.J., Svingen P.A., Atherton P., Bishop W.R., Kirschmeier P., Kaufmann S.H. A phase I trial of the farnesyl transferase inhibitor SCH 66336: evidence for biological and clinical activity. Cancer Res 2000, 60:1871-1877.
98. Feldman E.J., Cortes J., DeAngelo D.J., Holyoake T., Simonsson B., O'Brien S.G., Reiffers J., Turner A.R., Roboz G.J., Lipton J.H., Maloisel F., Colombat P., Martinelli G., Nielsen J.L., Petersdorf S., Guilhot F., Barker J., Kirschmeier P., Frank E., Statkevich P., Zhu Y., Loechner S., List A. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 2008, 22:1707-1711.
99. Lancet J.E., Gojo I., Gotlib J., Feldman E.J., Greer J., Liesveld J.L., Bruzek L.M., Morris L., Park Y., Adjei A.A., Kaufmann S.H., Garret-Mayer E., Greenberg P.L., Wright J.J., Karp J.E. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007, 109:1387-1394.
100. Harousseau J.L., Martinelli G., Jedrzejczak W.W., Brandwein J.M., Bordessoule D., Masszi T., Ossenkoppele G.J., Alexeeva J.A., Beutel G., Maertens J., Vidriales M.B., Dombret H., Thomas X., Burnett A.K., Robak T., Khuageva N.K., Golenkov A.K., Tothova E., Mollgard L., Park Y.C., Bessems A., De Porre P., Howes A.J. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009, 114:1166-1173. FIGHT-AML-301 Investigators.
101. Jabbour E., Kantarjian H., Ravandi F., Garcia-Manero G., Estrov Z., Verstovsek S., O'Brien S., Faderl S., Thomas D.A., Wright J.J., Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 2010, 2010 Oct 19. [Epub ahead of print].
102. Johnston S.R., Hickish T., Ellis P., Houston S., Kelland L., Dowsett M., Salter J., Perez-Ruixo J.J., Palmer P., Howes A. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003, 21:2492-2499.
103. Dalenc F., Doisneau-Sixou S.F., Allal B.C., Marsili S., Lauwers-Cances V., Chaoui K., Schiltz O., Monsarrat B., Filleron T., Renée N., Malissein E., Meunier E., Favre G., Roché H. Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. Clin Cancer Res 2010, 16:1264-1271.
104. Khuri F.R., Glisson B.S., Kim E.S., Statkevich P., Thall P.F., Meyers M.L., Herbst R.S., Munden R.F., Tendler C., Zhu Y., Bangert S., Thompson E., Lu C., Wang X.M., Shin D.M., Kies M.S., Papadimitrakopoulou V., Fossella F.V., Kirschmeier P., Bishop W.R., Hong W.K. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004, 10:2968-2976.
105. Kim E.S., Kies M.S., Fossella F.V., Glisson B.S., Zaknoen S., Statkevich P., Munden R.F., Summey C., Pisters K.M., Papadimitrakopoulou V., Tighiouart M., Rogatko A., Khuri F.R. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 2005, 104:561-569.
106. Cohen S.J., Ho L., Ranganathan S., Abbruzzese J.L., Alpaugh R.K., Beard M., Lewis N.L., McLaughlin S., Rogatko A., Perez-Ruixo J.J., Thistle A.M., Verhaeghe T., Wang H., Weiner L.M., Wright J.J., Hudes G.R., Meropol N.J. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003, 21:1301-1306.
107. Hanrahan E.O., Kies M.S., Glisson B.S., Khuri F.R., Feng L., Tran H.T., Ginsberg L.E., Truong M.T., Hong W.K., Kim E.S. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009, 32:274-279.
108. Adjei A.A., Davis N., Erlichman C., Svingen P.A., Kaufmann S.H. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000, 6:2318-2325.
109. Raponi M., Lancet J.E., Fan H., Dossey L., Lee G., Gojo I., Feldman E.J., Gotlib J., Morris L.E., Greenberg P.L., Wright J.J., Harousseau J.L., Löwenberg B., Stone R.M., De Porre P., Wang Y., Karp J.E. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008, 111:2589-2596.
110. Kieran M.W., Gordon L., Kleinman M. New approaches to progeria. Pediatrics 2007, 120:834-841.
111. De Sandre-Giovannoli A., Bernard R., Cau P., Navarro C., Amiel J., Boccaccio I., Lyonnet S., Stewart C.L., Munnich A., Le Merrer M., Lévy N. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003, 300:2055.
112. Eriksson M., Brown W.T., Gordon L.B., Glynn M.W., Singer J., Scott L., Erdos M.R., Robbins C.M., Moses T.Y., Beglund P., Dutra A., Pak E., Durkin S., Csoka A.B., Boehnke M., Glover T.W., Collins F.S. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003, 423:293-298.
113. Worman H.J., Fong L.G., Muchir A., Young S.G. Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest 2009, 119:1825-1836.
114. Goldman R.D., Shumaker D.K., Erdos M.R., Eriksson M., Goldman A.E., Gordon L.B., Gruenbaum Y., Khuon S., Mendez M., Varga R., Collins F.S. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2004, 101:8963-8968.
115. Merideth M.A., Gordon L.B., Clauss S., Sachdev V., Smith A.C., Perry M.B., Brewer C.C., Zalewski C., Kim H.J., Solomon B., Brooks B.P., Gerber L.H., Turner M.L., Domingo D.L., Hart T.C., Graf J., Reynolds J.C., Gropman A., Yanovski J.A., Gerhard-Herman M., Collins F.S., Nabel E.G., Cannon R.O., Gahl W.A., Introne W.J. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 2008, 358:592-604.
116. Olive M., Harten I., Mitchell R., Beer J.K., Djabali K., Cao K., Erdos M.R., Blair C., Funke B., Smoot L., Gerhard-Herman M., Machan J.T., Kutys R., Virmani R., Collins F.S., Wight T.N., Nabel E.G., Gordon L.B. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010, 30:2301-2309.
117. Davies B.S., Fong L.G., Yang S.H., Coffinier C., Young S.G. The posttranslational processing of prelamin A and disease. Annu Rev Genomics Hum Genet 2009, 10:153-174.
118. Yang S.H., Bergo M.O., Toth J.I., Qiao X., Hu Y., Sandoval S., Meta M., Bendale P., Gelb M.H., Young S.G., Fong L.G. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA 2005, 102:10291-10296.
119. Capell B.C., Erdos M.R., Madigan J.P., Fiordalisi J.J., Varga R., Conneely K.N., Gordon L.B., Der C.J., Cox A.D., Collins F.S. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005, 102:12879-12884.
120. Fong L.G., Frost D., Meta M., Qiao X., Yang S.H., Coffinier C., Young S.G. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006, 311:1621-1623.
121. Yang S.H., Meta M., Qiao X., Frost D., Bauch J., Coffnier C., Majumdar S., Bergo M.O., Young S.G., Fong L.G. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 2006, 116:2115-2121.
122. Capell B.C., Olive M., Erdos M.R., Cao K., Faddah D.A., Tavarez U.L., Conneely K.N., Qu X., San H., Ganesh S.K., Chen X., Avallone H., Kolodgie F.D., Virmani R., Nabel E.G., Collins F.S. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA 2008, 105:15902-15907.
123. Otto J.C., Casey P.J. The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells. J Biol Chem 1996, 271:4569-4572.
124. Bordier B.B., Ohkanda J., Liu P., Lee S.Y., Salazar F.H., Marion P.L., Ohashi K., Meuse L., Kay M.A., Casey J.L., Sebti S.M., Hamilton A.D., Glenn J.S. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003, 112:407-414.
125. Eastman R.T., Buckner F.S., Yokoyama K., Gelb M.H., Van Voorhis W.C. Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res 2006, 47:233-240.
126. Hast M.A., Fletcher S., Cummings C.G., Pusateri E.E., Blaskovich M.A., Rivas K., Gelb M.H., Van Voorhis W.C., Sebti S.M., Hamilton A.D., Beese L.S. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem Biol 2009, 16:181-192.
127. Tidyman W.E., Rauen K.A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009, 19:230-236.
128. Rauen K.A. HRAS and the Costello syndrome. Clin Genet 2007, 71:101-108.
129. Aoki Y., Niihori T., Kawame H., Kurosawa K., Ohashi H., Tanaka Y., Filocamo M., Kato K., Suzuki Y., Kure S., Matsubara Y. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005, 37:1038-1040.